Application of jejunal interposition after radical proximal gastrectomy.
- Author:
Bin ZHANG
1
;
She-qing JI
;
Ya-wei HUA
;
Ying-qiang LIU
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Anastomosis, Surgical; adverse effects; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; C-Reactive Protein; metabolism; Chemotherapy, Adjuvant; Female; Fluorouracil; therapeutic use; Follow-Up Studies; Gastrectomy; adverse effects; methods; Gastroesophageal Reflux; etiology; Humans; Jejunum; surgery; Leucovorin; therapeutic use; Male; Middle Aged; Operative Time; Organoplatinum Compounds; therapeutic use; Quality of Life; Reconstructive Surgical Procedures; adverse effects; methods; Retrospective Studies; Stomach Neoplasms; drug therapy; metabolism; surgery; Systemic Inflammatory Response Syndrome; etiology
- From: Chinese Journal of Oncology 2013;35(7):530-533
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore an ideal method of digestive tract reconstruction and tolerance to adjuvant chemotherapy after radical proximal gastrectomy.
METHODSThirty patients in the reconstruction group were treated by jejunal interposition, and other 30 patients received gastroesophagostomy (control group). The operation time, operation risk, occurrence of reflux esophagitis and postoperative 1-, 3-, 6-month nutrition statuses were evaluated. Forty-three patients received postoperative adjuvant chemotherapy with mFOLFOX-6 and tolerance to the chemotherapy was assessed.
RESULTSThe operation time of the reconstructional group was (162.2 ± 14.0)min and that of the control group was (137.6 ± 18.9)mi, with a statistically significant difference. (t = -5.7, P<0.01). There were no significant differences of operation risk, postoperative 2-, 4-, and 6-day C-reactive protein, 2-, 4- and 6-day systemic inflammatory response syndrome between the two groups. The differences of the occurrence of postoperative 1-, 3- and 6-month reflux esophagitis and 3- and 6-month nutritional status between the two groups were statistically significant. 18 of 19 (94.7%) patients in the reconstruction group completed all six cycles of chemotherapy, 24 patients in the control group received chemotherapy, and 12 (50.0%) of them completed 6 cycles of chemotherapy. There was a significant difference in the completion rate of chemotherapy of the two groups (P<0.05).
CONCLUSIONSThe postoperative complications of jejunal interposition are not inceased, the symptoms of reflux esophagitis are alleviated, the quality of life can be improved, and there is a better tolerance to adjuvant chemotherapy. Therefore, jejunal interposition after radical proximal gastrectomy is a rational method of digestive tract reconstruction.